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Abstract
Since delivered dose is rarely the same with planned, we calculated the delivered total dose to ten 
prostate radiotherapy patients treated with rectal balloons using deformable dose accumulation 
(DDA) and compared it with the planned dose. The patients were treated with TomoTherapy using 
two rectal balloon designs: five patients had the Radiadyne balloon (balloon A), and five patients 
had the EZ-EM balloon (balloon B). Prostate and rectal wall contours were outlined on each pre-
treatment MVCT for all patients. Delivered fractional doses were calculated using the MVCT 
taken immediately prior to delivery. Dose grids were accumulated to the last MVCT using DDA 
tools in Pinnacle3 ™ (v9.100, Philips Radiation Oncology Systems, Fitchburg, USA). Delivered 
total doses were compared with planned doses using prostate and rectal wall DVHs. The rectal 
NTCP was calculated based on total delivered and planned doses for all patients using the Lyman 
model. For 8/10 patients, the rectal wall NTCP calculated using the delivered total dose was less 
than planned, with seven patients showing a decrease of more than 5% in NTCP. For 2/10 patients 
studied, the rectal wall NTCP calculated using total delivered dose was 2% higher than planned. 
This study indicates that for patients receiving hypofractionated radiotherapy for prostate cancer 
with a rectal balloon, total delivered doses to prostate is similar with planned while delivered dose 
to rectal walls may be significantly different from planned doses. 8/10 patients show significant 
correlation between rectal balloon anterior-posterior positions and some VD values.
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Introduction
In external beam radiation therapy, the target dose is often limited by dose tolerance of the 
surrounding normal structures. With the increased use of image guided radiotherapy (IGRT) 
it is becoming evident that the delivered treatment dose is not necessarily what is planned. 
Thus, it is desirable to determine what dose is delivered during a treatment course (1,2). 
With knowledge of the delivered dose through image guidance techniques, one can monitor 
the achievable tumor control probability (TCP) while keeping the normal tissue 
complication probability (NTCP) within tolerance, a process termed ‘dose guidance’(3). 
Helical tomotherapy is one such image guided radiotherapy treatment system that 
incorporates a megavoltage fan beam CT (MVCT) scanner with fan-beam treatment 
delivery, allowing volumetric images of the anatomy to be obtained immediately prior to 
radiation delivery. As described in reference(3-5), dose guidance can only become a reality 
on tomotherapy when first, accurate calculation of delivered dose is achievable; secondly, 
one has the ability to reliably track four-dimensional target motion envelopes; and last, 
changes in the target can be reliably contoured and organ deformation can be quantified.
Several studies have discussed methods of calculating the delivered dose to the patient 
(6-12). It is necessary to have (i) repeated imaging of the patient (ii) methods to calculate the 
delivered dose for each fraction (iii) a tool to accumulate dose distribution to one reference 
image and (iv) consistent organ definition according to the patient’s planning image. The 
delivered dose can be calculated on multiple repeat images which are compared directly 
with the planned fractional dose, or can be summed using rigid and deformable methods to 
result in the total delivered dose to compare with the total planned dose.
In the present study, we explored the benefit of using total delivered dose calculated by 
deformable dose accumulation (DDA) workflow to estimate total absorbed dose by patient. 
We thus have calculated the delivered total dose to prostate cancer patients treated with 
helical tomotherapy with rectal balloons used as prostate immobilization devices. The 
delivered total dose was calculated using DDA of the dose calculated at multiple time points 
during treatment. The delivered total doses to the Planning Target Volume (PTV) and rectal 
wall were compared with the planned doses. In addition to dosimetric comparisons, the 
correlation between rectal balloon geometry and rectal dose was also investigated.
Materials and methods
Patient selection and Treatment Planning
Ten patients treated with rectal balloons were selected at random for dosimetric analysis 
from the database of our IRB approved prostate dose escalation study (RO-02803). Patients 
1 to 5 were treated with the Radiadyne rectal balloon (Radiadyne, USA) hereafter referred to 
as balloon A, and Patients 6 to 10 were treated with the EZ-EM balloon (EZ-EM, USA), 
hereafter referred to as balloon B. Balloon B consists of a latex-free inflatable retention cuff 
enema tip connected to a 60 cc syringe. It was later replaced in clinical use in our 
department by the latex- free balloon A, which has a midline groove when inflated and is 
fixed over an end of a shaft. All patients had a planning kVCT taken with the rectal balloon 
in place for initial treatment planning purposes. The scan covered the whole abdomen and 
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pelvic region. A 3 mm posterior margin and 5 mm margin in all other directions was applied 
to the prostate to obtain the PTV. Each patient received 12 fractions of 4.3 Gy to the PTV to 
a total dose of 51.6 Gy using the Hi-Art TomoTherapy delivery system (Accuray Inc., 
Sunnyvale, CA).
MVCT coverage
A MVCT was taken on Tomotherapy prior to delivery of each fraction for the purpose of 
daily patient setup verification. The scanned volume included several slices above and 
below the prostate. The MVCT image was rigidly registered to the planning kVCT using a 
combined soft tissue/bony anatomy algorithm employing four degrees of freedom (3 
translational degrees of freedom AP, LAT, and VERT, and one rotational degree of freedom 
(gantry roll)) to the planning kVCT. The registration parameters were stored in the 
TomoTherapy database for later use.
Calculation of the delivered dose and planned dose
The Planned Adaptive TomoTherapy software (v 4.1.0.0) was used to calculate the delivered 
dose for each fraction. The registration shift parameters used for treatment setup were 
applied to the MVCT for registration with the planning kVCT such that the patient’s MVCT 
was representing the patient’s estimated position on the treatment couch. Once registration 
had been carried out, the slices in the kVCT covered by the MVCT scanning volume were 
replaced with the MVCT data to result in a merged image for each fraction. The dose was 
then calculated on the merged image using the ‘delivery’ sinogram data, which is the 
planned sinogram corrected for gantry roll for a given fraction. This resulted in a merged 
image for each fraction with that fraction’s calculated dose using the delivery sinogram.
There are two issues with dose calculation using the MVCT that need to be taken into 
account. The first is the possible change of image value-to-density table (IVDT) over the 
course of treatment (6,13). As reported by Langen et al., over a period of five months, a 
difference of 4.7% in the HU values was observed in high-density regions. In our study, we 
found that changes in the IVDT can cause up to 0.3 Gy difference in dose calculation 
between two consecutive fractions. Ideally, an IVDT should be measured for every fraction 
delivered for a given patient. As this is a retrospective study, IVDT data corresponding to 
each fraction was not available. Instead of using the daily measured IVDT, a bulk density 
override was performed using a step-IVDT applied to each MVCT and kVCT so that the 
patient body physical density was 1 g/cm3 and the rectal balloon contents (air) was 0 g/cm3. 
The second issue is that the field of view of the MVCT is 40cm, which is sometimes not 
large enough to cover the lateral and anterior abdomen surface of patients. The merged 
MVCT in the adaptive planning station thus uses the kVCT to fill in missing tissue around 
the patient’s external contour in the MVCT. The above two corrections were applied to 
allow consistent dose accumulation that is independent of the IVDT and the amount of 
replaced tissue.
Target and normal tissues contouring
In order to study inter-fraction motion, the prostate and rectal wall were contoured on the 
merged image by the same investigator. The contours were drawn only on slices common to 
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all MVCT studies taken for a given patient. The prostate was outlined following a definition 
consistent with the planning prostate contours on the kVCT. The rectal wall Dose Volume 
Histogram (DVH) is regarded as a useful metric for prediction of rectal bleeding (14). The 
definition of rectal wall was a simple ring expansion of the inner rectal wall of 3 mm at the 
level of the balloon, and as a solid structure below the level of the balloon. Inter-observer 
contouring error was minimized for rectal wall, since we follow a three-step workflow: (a) 
using autocontour tool to delineate the inner rectal wall, which is identical with the rectal 
balloon; (b) generating a 3mm ring expansion of the inner rectal wall; (c) only keep the ring 
expansion contours on the image slices common to all MVCT studies taken for a given 
patient. This resulted in a set of prostate and rectal wall contours on each merged image with 
consistent superior-inferior spans. To facilitate comparison with the planned dose, the 
prostate and rectal wall were contoured on the planning kVCT only on the slices common 
with all MVCT data sets.
Deformable image registration (DIR) and Deformable Dose accumulation (DDA)
Whether DDA based on DIR benefits a patient group or not should be carefully explored in 
prospective clinical trials (4,15). Increasing and testing the voxel-by-voxel accuracy of DIR 
algorithm itself has been a field of active investigation (16-19). The methodology for DIR 
employed in this study and its clinical utility has been assessed and validated for the case of 
head and neck by expert physicians, who have rated the majority of the DIR-propagated 
organs at risk contours as requiring no or only minor modifications for clinical use (20). The 
interested reader is referred to Ref. [20] for a detailed description of the validation DIR 
workflow employed in this study. DIR and DDA hold great promise for improved prediction 
of normal tissue toxicity (4). Prostate cancer patients included in this study had rectal 
balloons placed yielding relatively consistent rectal wall volumes. For this reason we have 
decided to study only the dose to the rectal wall since the volumes of other normal tissues 
varied over the course of therapy calling into question the applicability of DIR and DDA. As 
a hollow organ, the surface is a reasonable approximation of the rectal shape; DIR-based 
propagation of the delineated rectal wall contours between the source and target MVCTs 
therefore provides a method to assess the accuracy of the DIR (21).
The DIR algorithms and contour propagation workflow used in this study have been 
implemented in a research version of the Pinnacle3 ™ treatment planning system (v9.100, 
Philips Radiation Oncology Systems, Fitchburg, WI, USA). The voxel-by-voxel DIR 
algorithm used was Fast Symmetric Demons DIR algorithm as implemented in the Insight 
Toolkit (22). The deformation vector field (DVF) from each merged MVCT to the 12th 
fraction merged MVCT was qualitatively investigated by applying the DVF to the source 
image to result in a DIR-approximation of the 12th faction merged image. The deformed 
image showed little difference when compared to the 12th fraction merged MVCT (Figure 
1(B)). We also used the DVF to non-rigidly propagate contours to check if propagated 
contours accurately outlined the anatomy of the target image (Figure 1(D)). Results show 
that for all of the ten patients, treated with either one of the balloons, DIR improved the 
registration accuracy over what could be achieved using rigid registration alone.
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DDA was performed using adaptive tools in the planning system described above. The 
process used for DDA is described in Figure 2. In particular DDA was achieved by warping 
each merged image and its dose grid to the 12th fraction’s merged MVCT image and 
summing the warped dose from each fraction to the dose of the 12th fraction resulting in the 
total delivered dose from all 12 fractions on the 12th merged MVCT image.
The prostate and rectal wall DVHs were calculated for the planned dose on the planning 
kVCT, for each fraction’s dose on the corresponding merged MVCT and for the total 
delivered dose on the 12th fraction merged MVCT. Since a step-IVDT was used to 
recalculate the planned doses, a scaling factor was applied to the recalculated planned dose 
prostate DVH and each fraction’s delivered DVH so that 50% of the prostate volume 
received a planned dose of 51.6 Gy or 4.3 Gy per fraction. Scaling was not applied to the 
total delivered doses on the 12th fraction since this consists of the already scaled fractional 
doses (Figure 2). Scaling factors were typically 0.9 - 0.94. For each rectal wall DVH, the 
corresponding generalized equivalent uniform dose (gEUD) was calculated and used to 
determine the rectal wall NTCP for each patient. The Lyman Kutcher Burman (LKB) NTCP 
model (23,24) was used with the following parameters m=0.13, n=0.09 and TD50=76.9 Gy 
that have been determined for the endpoint > Grade 2 late rectal bleeding as described in the 
QUANTEC Study (25). Since our ten patients received hypofractionated radiotherapy with a 
dose per fraction of 4.3 Gy, the prescription dose and DVHs were converted to equivalent 
dose in 2 Gy fractions (EQD2) DVHs using an α/β-ratio of 3 Gy, that is, normalized to a 
prescription dose of 75.4 Gy (EQD2=75.4Gy). Using these parameters our NTCP model 
takes the following form
where  and .
Di is the dose to relative volume νi in 2Gy per fraction equivalents, and the sum extends 
over all dose bins in the DVH.
Dosimetric effect of DDA error
The effect of errors in deformable dose accumulation and methods of how to mitigate them 
when employing the symmetric demon algorithm on the resulting dose volume histograms 
for target volumes and organs at risk have been described in Ref. (18,26-28). As pointed out 
in reference 18 even though DIR and DDA are not perfect and suffer from residual errors, 
estimates of toxicity or tumor control based on these methods are likely to be more 
representative of clinical reality, than estimates based on methods that ignore anatomical 
change and structure distortion through out treatment, and simply use the total planned dose 
to estimate expected normal tissue complications and local tumor control. The current study 
focuses on exploring the benefit of using the total delivered dose calculated employing the 
DDA workflow shown in Figure 2 to arrive at an estimate of total delivered dose to the 
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patient. To this end we compare the total planned dose for prostate and rectal wall with the 
total delivered doses to these structures in terms of dose volume histograms, VD and NTCP.
Errors that can impact the DDA workflow include inverse consistency and transitivity 
errors. When using DVFs that exhibit these types of errors, the total delivered dose to 
structures does depend on the image pathway taken during dose accumulation(18). In order 
to study how much the total delivered dose was affected by the DDA workflow, for each 
patient, we accumulated all of the 12 delivered fractional doses on each of the 12 daily 
images, and then calculated the NTCP for each of the total delivered doses resulting from 
each of the accumulation pathways taken to study the variation in NTCP.
Correlation study between balloon volume and delivered dose
The relationship between the updated delivered dose and the variation in the rectal balloon 
volume was investigated. The updated delivered dose was done by accumulating the 
delivered fractional doses to each MVCT, e.g. the first and second delivered fractional doses 
were accumulated to the second MVCT yielding a second updated delivered dose. The 
fractional volumes receiving high, intermediate and low doses - V75, V70, V50, and V30 - 
were studied. These were firstly converted from 2 Gy/fraction doses to our fractionation 
scheme using α/β = 3 Gy (V51.37, V47.95, V34.25 and V20.55) and then converted to updated 
delivered doses (e.g. for the second updated delivered dose, V8.56, V8.00, V5.7 and V3.42). 
The difference between the planned and updated delivered fractional volumes receiving 
these doses was then calculated using the planned and updated delivered rectal wall DVHs. 
The possible correlation between balloon volume and dose volumes was investigated using 
the Spearman’s rank correlation test. The Spearman’s rank correlation test is a non-
parametric test that measures how well the relationship between two variables is described 
by a monotonic relationship.
Correlation of balloon position with delivered dose
It is also natural to ask if the positioning of the balloon affects the delivery of the planned 
dose. We delineated balloons on the same slices of MVCTs as we contoured prostates and 
rectal walls, and calculated the center of balloon for these balloon contours. The delivered 
dose used here were actually the updated delivered dose as mentioned in previous session. A 
correlation study between the changes of the 3D coordinates of the center of the balloon 
contours and the changes of VD was performed.
Results
Inter-fractional dose variation
The delivered fractional dose prostate DVHs show consistency with the planned prostate 
DVH shape (Figure 3). With the exception of Patients 3 and 7, there is minimal inter-
fraction variation of the delivered dose to prostate for each fraction, as expected since daily 
IGRT with target realignment to compensate for internal target motion was employed. 
Patient 3 and Patient 7 exhibit a loss of coverage of the prostate, seen by the more rounded 
shoulders of the prostate DVH curves. To facilitate comparison to other studies we have 
collected In Table I the minimum dose covering the prostate (Dmin) and the dose covering 
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95% of prostate volume (D95). There exists some inter-fraction variation in the delivered 
fractional dose rectal wall DVHs, however the overall shape is generally maintained (Figure 
3(A, E) for patients treated with balloon A and Figure 3(F, J) for patients treated with 
balloon B). The volume of rectal wall (also, the volume of the rectal balloon) for each 
fraction has large effect on the volume receiving a given dose level over the course of 
therapy.
Total treatment dose variation
The normalized DVH curves show very little difference between the planned and total 
delivered prostate dose (Figure 4(A-E) for patients treated with balloon A, (F-J) for patients 
treated with balloon B). The total delivered dose D50 was within ± 2% of the planned dose 
prostate D50.
Figure 4 shows that the volumes receiving higher doses in the total delivered rectal wall 
DVHs were much lower than planned for 7/10 patients. The only two patients showing 
slightly more volume receiving high dose were treated with balloon A.
In order to quantify the setup consistency through out the treatment process, the balloon 
volumes for all fractions were measured on the slices that were in common for all image sets 
(Table I). Nine out of ten patients show minimal changes in volume over the course of the 
treatment, showing that consistent filling of the balloon was achieved in most cases. For one 
patient treated with balloon A (patient 3), the standard deviation (SD) of the balloon volume 
was above 15mL, and the maximum volume (Vmax) is almost double of the average volume 
(Vavg).
The calculated rectal wall NTCPs for the planned and delivered doses are shown in Table II. 
For three out of ten patients (patient 2, 3 and 6), there were minimal differences in the rectal 
NTCP between the total delivered and planned dose. For the seven that had significant DVH 
differences, the NTCP calculated from the total delivered dose is less than that from the 
planned dose by 5 – 10%. Two patients show slightly increased delivered dose NTCP 
(patients 2 and 3) compared to their planned dose NTCP, which were also the only two 
patients not to exhibit a decrease in V75 (Table II).
The difference in V75, V70, V50 and V30 between planned dose DVH and total delivered 
dose DVH were measured for each patient (Table II). Differences larger than 10% were 
found for Patient 1 for V70 and V75, Patient 5 for V30, V50, V70 and V75, Patient 7 for V30 
and V70, Patient 8 for V70 and V75, Patient 9 for V75 and Patient 10 for V70 and V75.
Error study for DDA—Results show the NTCP change caused by inverse consistency and 
transitivity uncertainties in the DDA process is 3.1- 6.1 % having 95% confidence interval 
widths from ±0.6-±1.1 % (Table III).
Correlation study between rectal balloon volume and VD
Table IV shows the correlation coefficients between each dose volume parameter and each 
balloon volume for all patients. For patients treated with balloon A, only for patient 5 did all 
four VD values strongly correlate with balloon volumes. For 3 of the 5 patients treated with 
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balloon B, some of the VD values show strong correlation with balloon volume. For 3 out of 
10 patients, statistically significant positive strong correlation between V75 and balloon 
volume was found, meaning for these 3 patients as the volume of the balloon increased, so 
did the V75. Although most correlations between balloon volume and dose were positive, 
meaning volumes receiving given doses increased with increasing balloon volume, there 
were some patients for whom a negative correlation between balloon volume and dose 
volume parameters was observed. These correlations however, were not statistically 
significant.
Correlation study between center of balloon and VD
Results show that for 8 of the 10 patients, the changes of the anterior-posterior direction 
coordinates of the center of rectal balloon are strongly correlation with some VD values 
(Table V). For 4 of the 10 patients, the changes of the superior-inferior direction coordinates 
of the center of rectal balloon are strongly correlation with some VD values. No strong 
correlation was found between the changes of the left-right direction coordinates of the 
center of rectal balloon and VD values.
For patients 5 and 7, the changes of the anterior-posterior and superior-inferior direction 
coordinates of the center of rectal balloon are strongly correlated with all of the VD values. 
The correlation coefficients in anterior-posterior part of Table V are all positive, which 
means as the balloon position shifts posteriorly, the VD decreases. For patient 5, the 
correlation coefficients in superior-inferior part of Table V are all positive, which means as 
balloon position shifts superiorly, the VD decreases. However, for patient 7, the correlation 
coefficients in superior-inferior part of Table V are all negatives, which means as balloon 
position shifts superiorly, the VD increases.
Discussion
Comparison with published studies
The validity of using MVCT to calculate dose has been discussed by Langen et al. (6) in 
2005. Kupelian et al. (11) studied the delivered dose from full courses of external beam 
radiotherapy for prostate patients using daily MVCT imaging. It was found that the prostate 
did receive the planned radiation dose, however, they also found significant daily variation 
in rectal and bladder doses without apparent pattern from patient to patient, or within 
individual patients. In 2010, Hatton et al. (8) assessed the 5-field conformal plan dose 
delivery using cone-beam CT (CBCT) taken twice a week. The initial plan was calculated 
on all CBCT scans to compare a group of delivered doses to the planned dose. It was found 
that planned doses to the prostate were not achieved for all patients, and that the rectal and 
bladder doses were higher than planned. In contrast to these studies, in the current 
retrospective study, we have investigated patients treated with rectal balloons. DIR was used 
to accumulate doses to a single image to compare the delivered dose to the planned dose. 
We found planned target doses were achieved for all of the patients studied, while total 
delivered dose to rectal wall were mostly lower than planned. Despite sophisticated image 
guidance and the use of rectal balloons, some variation in the delivered rectal wall dose was 
observed. The difference between delivered dose and planned dose for target and normal 
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tissue depends on the institution’s setup and image guidance techniques as well as patient 
specific factors. In clinical scenario, it could be advantageous apply an adaptive protocol 
whereby the delivered dose (and calculated tumor control and normal tissue toxicity 
probability) is monitored during the treatment process, so that deviations from the plan can 
be corrected, or dose can be escalated safely.
The usage of rectal balloon during radiotherapy was to consistently localize the prostate and 
the rectal wall through the treatment delivery. For half of the patients, the V75 and V70 on 
total delivered dose DVHs were more than 10% lower than planned dose DVHs. In addition, 
for most of the patients studied, the total delivered dose NTCP was lower than planned dose 
NTCP by more than 5%, which meant that planned dose NTCP did not represent the total 
delivered NTCP. The planned dose rectal wall DVH does not represent the total delivered 
dose rectal wall DVH well. One possible reason could be that the rectal wall voxels in high 
dose regions were not always the same ones from fraction to fraction. This supports the 
findings of several published studies that have pointed out that normal tissues exhibit 
significant variation in position, shape, and volume during radiotherapy were prone to dose 
uncertainties(12,29-31).
Does DDA help to estimate delivered dose?
Numerical methods have been developed to quantitatively evaluate DIR algorithm, 
including use of contours and landmarks identified on both target and source images(16), 
use of phantoms with known physical deformation or phantoms with easily identifiable 
markers where motion can be accurately measured(32). There also exists method to analyze 
patterns of uncertainty in DVF measurements and their effect on dose mapping in image 
guided adaptive radiotherapy(19). In this study, the DIR algorithm worked well for prostate 
cancer patients treated with balloons in the aspects of prostate and rectal wall contour 
propagations, and the agreement of deformed images with target images. The 95% 
confidence interval of the total delivered dose NTCP is relatively small compared with the 
difference between total delivered dose and planned dose NTCPs. When DIR algorithms 
with small inverse consistency and transitivity errors are implemented in dose accumulation, 
the total delivered dose should vary little by the image pathway taken(18).
The implementation of DDA used in this study utilized trilinear interpolation to deform dose 
from one image to another. That is, the vector pointing from the target image voxel was used 
to determine the dose at the corresponding anatomical location in the source image, using 
trilinear interpolation to reduce the effects of the voxel correlation not being a true one-to-
one correspondence. This method has been shown to introduce errors in DDA due to the 
possible rearrangement of the energy deposition per unit mass, which increases with dose 
and density gradients and voxel size(26,28). Proposed solutions require the use of monte 
carlo algorithms for dose calculation, so as to warp the energy deposition accordingly, which 
was not available in the current study. Thus, there will be some inherent uncertainty in the 
presented results due to this effect. This uncertainty however also reduces with voxel 
size(26,27); the voxel size used in this study (0.195 × 0.195 × 0.25 cm3), so we expect the 
errors in this study to be sufficiently lower than the errors one would observe without doing 
DDA.
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Although it is shown in Figure 3 that one can observe deviations of the delivered dose from 
the planned dose on a fraction by fraction basis, DDA provides a single delivered dose 
distribution which has combined all delivered fractional doses up to that point. This is useful 
and arguably required when looking at an adaptive radiotherapy paradigm, where decisions 
on modification of the treatment plan based on the delivered dose need to be made using the 
most accurate information. This is of particular importance in heterogeneous dose 
distributions such as that seen by the rectum, so that any hot or cold spots seen by the organ 
in each fraction are summed appropriately in the context of hot and cold spots from other 
fractions. It is of lesser importance when highly homogenous dose distributions are seen by 
the organ, such as the prostate in the current study.
Conclusions
This retrospective study investigated the delivered doses to prostate cancer patients 
receiving hypofractionated radiotherapy with rectal balloons using dose calculated on daily 
MVCTs and accumulated on the final treatment fraction image. Delivered prostate doses 
were found to be close to planned doses for all patients and delivered rectal doses were 
lower than the planned rectal dose for eight out of ten patients. Additionally, seven patients 
showed significantly decreased delivered NTCP as compared to planned NTCP. Eight 
patients showed significant a correlation between the rectal balloon anterior-posterior 
position and some VD values, i.e. as the balloon position moved posteriorly, the VD 
decreased. DDA is not necessarily required for estimation of the delivered dose to the 
prostate, due to the highly homogenous dose distribution seen by the prostate. However, 
DDA is highly useful in comparing the total delivered dose with the planned dose in 
heterogeneous dose distributions such as that seen by the rectal wall, particularly in the 
context of plan adaptation during the course of radiotherapy.
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Abbreviation
DIR deformable image registration
DDA deformable dose accumulation
gEUD generalized equivalent uniform dose
NTCP normal tissue complication probability
TCP tumor control probability
IGRT image guided radiotherapy
MVCT megavoltage fan beam computerized tomography
DVH dose volume histogram
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PTV planning target volume
IVDT image value-to-density table
DVF deformation vector field
EQD2 equivalent dose in 2 Gy fractions
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Figure 1. 
(A): Fusion of source image (in inverse-grayscale) and target image (in grayscale) show 
differences between the two; (B): fusion of the deformed image (in inverse-grayscale) and 
target image (in grayscale) show reduced differences between the two; (C): Original 
contours for prostate and rectal wall (Red and Purple); (D): After propagation, the new 
contours (Blue and Green) delineate prostate and rectal wall on the right image with good 
agreement.
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Figure 2. 
Workflow of planning dose DVH calculation and total delivered dose DVH calculation.
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Figure 3. 
The first column shows the normalized volume delivered fractional dose prostate DVH (red 
line) for patients treated with balloon A (P1 stands for patient 1). The second column shows 
the absolute volume delivered fractional dose rectum DVH (blue line) for patients treated 
with balloon A. The third column shows the normalized volume delivered fractional dose 
prostate DVH (red line) for patients treated with balloon B. The fourth column shows the 
absolute volume delivered fractional dose DVH (blue line) for patients treated with balloon 
B.
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Figure 4. 
The first column shows the normalized total delivered dose DVH (dashed line) compared to 
the planned dose DVH (solid line) for patients treated with balloon A (P1 stands for patient 
1). The second column shows the normalized total delivered dose DVH (dashed line) 
compared to the planned dose DVH (solid line) for patients treated with balloon B. The 
prostate DVHs are in red and the rectal wall DVHs are in blue.
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Table II
Calculated rectal wall NTCPs for the planned and total delivered doses. A negative NTCP change means the 
NTCP calculated from the total delivered dose is less than that for the planned dose. NTCP Changes larger 
than +/−5% are shown in Bold. Changes of V30, V50, V70 and V75 between planned DVH and total delivered 
DVH are also shown. VD changes larger than +/− 10% are shown in Bold.
Balloon Patient PlannedNTCP
Delivered
NTCP
NTCP
change
Change of VD
V30 V50 V70 V75
A
1 16.6% 7.3% −9.4% −5% −4% −14% −16%
2 15.5% 17.9% 2.4% −2% 0 2% 3%
3 4.4% 6.5% 2.1% 9% 8% 3% 2%
4 24.0% 18.5% −5.5% −7% −6% −6% −9%
5 19.3% 8.8% −10.6% −11% −11% −15% −20%
B
6 14.0% 11.8% −2.3% −6% −2% −4% −5%
7 13.4% 8.0% −5.4% −20% −5% −10% −5%
8 17.8% 10.6% −7.2% −4% −8% −11% −12%
9 21.7% 12.9% −8.8% −5% −6% −9% −22%
10 16.5% 8.4% −8.1% −3% −9% −11% −13%
Technol Cancer Res Treat. Author manuscript; available in PMC 2015 August 31.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yu et al. Page 20
Ta
bl
e 
III
Pl
an
ne
d 
do
se
 N
TC
P 
as
 c
al
cu
la
te
d 
on
 th
e 
pl
an
ni
ng
 K
V
CT
, a
ve
ra
ge
 N
TC
P 
fo
r t
ot
al
 d
el
iv
er
ed
 d
os
es
 o
n 
di
ffe
re
nt
 d
ai
ly
 M
V
CT
’s
, a
nd
 th
e 
di
ffe
re
nc
e 
be
tw
ee
n 
m
ax
im
um
 a
nd
 m
in
im
um
 N
TC
P 
fo
r t
ot
al
 d
el
iv
er
ed
 d
os
es
 o
n 
di
ffe
re
nt
 d
ai
ly
 M
V
CT
’s
. S
ta
nd
ar
d 
de
vi
at
io
ns
 o
f N
TC
Ps
 fo
r t
ot
al
 d
el
iv
er
ed
 d
os
es
 o
n 
di
ffe
re
nt
 
da
ily
 M
V
CT
’s
 a
nd
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
s o
f N
TC
Ps
 fo
r t
ot
al
 d
el
iv
er
ed
 d
os
es
 o
n 
di
ffe
re
nt
 d
ai
ly
 M
V
CT
’s
 ar
e a
lso
 sh
ow
n.
Pa
tie
nt
1
2
3
4
5
6
7
8
9
10
Pl
an
ne
d
N
TC
P
16
.6
%
15
.5
%
4.
4%
24
.0
%
19
.3
%
14
.0
%
13
.4
%
17
.8
%
21
.7
%
16
.5
%
A
ve
ra
ge
N
TC
P
7.
1%
18
.1
%
7.
5%
20
.6
%
9.
5%
13
.3
%
8.
3%
11
.5
%
15
.2
%
7.
9%
M
A
X
-
M
IN
6.
1%
3.
4%
5.
9%
3.
7%
4.
1%
3.
8%
3.
1%
5.
7%
5.
0%
4.
8%
SD
1.
7%
1.
1%
1.
7%
1.
2%
1.
2%
1.
2%
1.
0%
1.
9%
1.
7%
1.
4%
95
%
Co
nf
id
en
ce
In
te
rv
al
w
id
th
±
1.
0%
±
0.
6%
±
1.
0%
±
0.
7%
±
0.
7%
±
0.
7%
±
0.
6%
±
1.
1%
±
1.
0%
±
0.
8%
Technol Cancer Res Treat. Author manuscript; available in PMC 2015 August 31.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yu et al. Page 21
Ta
bl
e 
IV
Sp
ea
rm
an
’s
 ra
nk
 c
or
re
la
tio
n 
te
st 
ρ v
al
ue
 fo
r e
ac
h 
pa
tie
nt
 p
er
fo
rm
ed
 b
et
w
ee
n 
ba
llo
on
 v
ol
um
e 
ch
an
ge
 a
nd
 c
ha
ng
e 
of
 V
30
,
 
V
50
,
 
V
70
 
an
d 
V
75
 
(to
p).
 T
he
 
Sp
ea
rm
an
 ra
nk
 c
or
re
la
tio
n 
co
ef
fic
ie
nt
s s
ho
w
n 
in
 B
ol
d 
in
di
ca
te
 a
 st
at
ist
ic
al
ly
 si
gn
ifi
ca
nt
 c
or
re
la
tio
n 
be
tw
ee
n 
ba
llo
on
 v
ol
um
e 
an
d 
th
e 
in
di
ca
te
d 
do
sim
et
ric
 
v
o
lu
m
e 
pa
ra
m
et
er
 a
t t
he
 p
 =
 0
.0
5 
le
ve
l.
C
or
re
la
tio
n 
te
st
 b
et
w
ee
n 
Ba
llo
on
 V
ol
um
e c
ha
ng
e a
nd
 V
D
Pa
tie
nt
1
2
3
4
5
6
7
8
9
10
V
30
0.
54
0.
1
0.
5
0.
17
0.
90
0.
34
0.
2
0.
5
0.
52
0.
85
V
50
0.
22
0.
22
0.
57
0.
2
0.
78
0.
66
−
0.
12
0.
38
0.
73
0.
85
V
70
−
0.
06
0.
38
0.
33
0.
15
0.
75
0.
8
0.
39
0.
45
0.
85
0.
8
V
75
−
0.
42
0.
29
0.
4
0.
05
0.
68
0.
83
0.
36
0.
38
0.
66
0.
38
Technol Cancer Res Treat. Author manuscript; available in PMC 2015 August 31.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yu et al. Page 22
Ta
bl
e 
V
Sp
ea
rm
an
’s
 ra
nk
 c
or
re
la
tio
n 
te
st 
re
su
lts
 fo
r e
ac
h 
pa
tie
nt
 p
er
fo
rm
ed
 b
et
w
ee
n 
ba
llo
on
 c
en
tra
l p
os
iti
on
 c
ha
ng
e 
an
d 
ch
an
ge
 o
f V
30
,
 
V
50
,
 
V
70
 
an
d 
V
75
.
 
Th
e 
Sp
ea
rm
an
 ra
nk
 c
or
re
la
tio
n 
co
ef
fic
ie
nt
s s
ho
w
n 
in
 B
ol
d 
in
di
ca
te
 a
 st
at
ist
ic
al
ly
 si
gn
ifi
ca
nt
 c
or
re
la
tio
n 
be
tw
ee
n 
ba
llo
on
 v
ol
um
e 
an
d 
th
e 
in
di
ca
te
d 
do
sim
et
ric
 
v
o
lu
m
e 
pa
ra
m
et
er
 a
t t
he
 p
 =
 0
.0
5 
le
ve
l.
Pa
tie
nt
1
2
3
4
5
6
7
8
9
10
Le
ft 
-
R
ig
ht
V
30
−
0.
25
0.
46
−
0.
55
0.
56
−
0.
11
−
0.
29
−
0.
09
0.
38
−
0.
14
−
0.
48
V
50
−
0.
08
0.
43
−
0.
56
0.
45
−
0.
2
−
0.
27
0.
1
0.
31
−
0.
26
−
0.
38
V
70
0.
13
−
0.
07
−
0.
1
0.
5
−
0.
13
0.
00
0.
09
0.
12
−
0.
47
−
0.
49
V
75
0.
44
−
0.
3
−
0.
18
0.
49
−
0.
09
0.
09
0.
03
0.
32
−
0.
53
−
0.
44
A
nt
 -
Po
st
V
30
0.
13
0.
64
0.
48
0.
13
0.
87
0.
74
0.
77
0.
8
0.
57
0.
63
V
50
0.
22
0.
65
0.
4
0.
13
0.
89
0.
52
0.
93
0.
93
0.
61
0.
75
V
70
0.
26
0.
35
0.
67
0.
18
0.
85
0.
63
0.
86
0.
87
0.
71
0.
84
V
75
0.
09
0.
16
0.
59
0.
3
0.
85
0.
59
0.
74
0.
82
0.
54
0.
67
Su
pe
rio
r -
In
fe
rio
r
V
30
0.
52
−
0.
01
0.
52
0.
44
0.
91
0.
10
−
0.
63
−
0.
25
0.
8
−
0.
8
V
50
0.
05
0.
11
0.
4
0.
42
0.
68
0.
51
−
0.
6
0.
05
0.
68
−
0.
79
V
70
−
0.
25
0.
38
−
0.
08
0.
3
0.
65
0.
37
−
0.
81
0.
17
0.
43
−
0.
78
V
75
−
0.
57
0.
39
−
0.
07
0.
17
0.
58
0.
20
−
0.
8
−
0.
02
−
0.
04
−
0.
35
Technol Cancer Res Treat. Author manuscript; available in PMC 2015 August 31.
